

# Pierre Wallemacq

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/10752454/pierre-wallemacq-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

64  
papers

3,010  
citations

27  
h-index

54  
g-index

68  
ext. papers

3,530  
ext. citations

3.7  
avg, IF

4.42  
L-index

#	Paper	IF	Citations
64	Impact of drug adherence on blood pressure response to alcohol-mediated renal denervation.. <i>Blood Pressure</i> , <b>2022</b> , 31, 109-117	1.7	1
63	Adherence to antihypertensive drug treatment in kidney transplant recipients. <i>Blood Pressure</i> , <b>2021</b> , 30, 411-415	1.7	
62	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 150-200	3.2	17
61	Assessment of adherence to diuretics and Eblockers by serum drug monitoring in comparison to urine analysis. <i>Blood Pressure</i> , <b>2020</b> , 29, 291-298	1.7	2
60	Comparative in vitro antimicrobial potency, stability, colouration and dissolution time of generics versus innovator of meropenem in Europe. <i>International Journal of Antimicrobial Agents</i> , <b>2020</b> , 55, 105825	14.3	2
59	Measuring Intracellular Concentrations of Calcineurin Inhibitors: Expert Consensus from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Expert Panel. <i>Therapeutic Drug Monitoring</i> , <b>2020</b> , 42, 665-670	3.2	6
58	Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , <b>2020</b> , 45, 703-713	2.7	7
57	Benefit of serum drug monitoring complementing urine analysis to assess adherence to antihypertensive drugs in first-line therapy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0237383	3.7	5
56	Fatal e-cigarette or vaping associated lung injury (EVALI): a first case report in Europe. <i>European Respiratory Journal</i> , <b>2020</b> , 56,	13.6	5
55	Predictors of blood pressure control in patients with resistant hypertension after intensive management in two expert centres: the Brussels-Torino experience. <i>Blood Pressure</i> , <b>2019</b> , 28, 336-344	1.7	5
54	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2019</b> , 41, 261-307	3.2	163
53	Temocillin plasma and pancreatic tissue concentrations in a critically ill patient with septic shock. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 1459-1461	5.1	1
52	Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. <i>Blood Pressure</i> , <b>2018</b> , 27, 358-367	1.7	11
51	SaO025PREVALENCE AND RISK FACTORS OF CHRONIC KIDNEY DISEASE (CKD) IN SOUTH KIVU, DEMOCRATIC REPUBLIC OF CONGO (DRC): A POPULATION-BASED STUDY. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i325-i325	4.3	
50	The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study. <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 452-454	3.5	12
49	Evaluation of Adherence Should Become an Integral Part of Assessment of Patients With Apparently Treatment-Resistant Hypertension. <i>Hypertension</i> , <b>2016</b> , 68, 297-306	8.5	99
48	Pharmacogenetic-based strategy using de novo tacrolimus once daily after kidney transplantation: prospective pilot study. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1019-27	2.6	7

47	Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S57-69	3.2	39
46	First report of imatinib measurement in hair: Method development and preliminary evaluation of the relation between hair and plasma concentrations with therapeutic response in chronic myeloid leukemia. <i>Clinica Chimica Acta</i> , <b>2016</b> , 453, 42-7	6.2	9
45	Barcelona Consensus on Biomarker-Based Immunosuppressive Drugs Management in Solid Organ Transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38 Suppl 1, S1-20	3.2	57
44	Therapeutic Drug Monitoring of Everolimus: A Consensus Report. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 143-69	3.2	71
43	Assuring the Proper Analytical Performance of Measurement Procedures for Immunosuppressive Drug Concentrations in Clinical Practice: Recommendations of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology Immunosuppressive Drug Scientific Committee. <i>Therapeutic Drug Monitoring</i> , <b>2016</b> , 38, 170-89	3.2	65
42	Fast method for simultaneous quantification of tamoxifen and metabolites in dried blood spots using an entry level LC-MS/MS system. <i>Clinical Biochemistry</i> , <b>2016</b> , 49, 1295-1298	3.5	13
41	Validation of a HPLC-MS/MS assay for the determination of total and unbound concentration of temocillin in human serum. <i>Clinical Biochemistry</i> , <b>2015</b> , 48, 542-5	3.5	9
40	Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. <i>Thrombosis Research</i> , <b>2015</b> , 135, 852-60	8.2	23
39	CYP3A4*22 is related to increased plasma levels of 4-hydroxytamoxifen and partially compensates for reduced CYP2D6 activation of tamoxifen. <i>Pharmacogenomics</i> , <b>2015</b> , 16, 601-17	2.6	23
38	Plasma and intracellular pharmacokinetic-pharmacodynamic analysis of mycophenolic acid in de novo kidney transplant patients. <i>Clinical Biochemistry</i> , <b>2015</b> , 48, 401-5	3.5	12
37	Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots--development, validation and clinical application during breast cancer adjuvant therapy. <i>Talanta</i> , <b>2015</b> , 132, 775-84	6.2	46
36	Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2015</b> , 70, 207-16	5.1	42
35	Impact of Laboratory Practices on Interlaboratory Variability in Therapeutic Drug Monitoring of Immunosuppressive Drugs. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 718-24	3.2	35
34	Application of the characteristic function to evaluate and compare analytical variability in an external quality assessment scheme for serum ethanol. <i>Clinical Chemistry</i> , <b>2015</b> , 61, 948-54	5.5	8
33	Resveratrol increases F508del-CFTR dependent salivary secretion in cystic fibrosis mice. <i>Biology Open</i> , <b>2015</b> , 4, 929-36	2.2	16
32	Multi-center analytical evaluation of a novel automated tacrolimus immunoassay. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 1069-77	3.5	26
31	Is plasma and urine neutrophil gelatinase-associated lipocalin (NGAL) determination in donors and recipients predictive of renal function after kidney transplantation?. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 68-72	3.5	26
30	Could trisialotransferrin be used as an additional biomarker to CDT in order to improve detection of chronic excessive alcohol intake?. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 1203-8	3.5	3

29	Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1207-21	2.6	23
28	Population pharmacokinetic analysis of tacrolimus early after pediatric liver transplantation. <i>Therapeutic Drug Monitoring</i> , <b>2014</b> , 36, 54-61	3.2	22
27	Validation of a rapid liquid chromatography-tandem mass spectrometric assay for the determination of octreotide plasma concentrations. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 139-41	3.5	9
26	Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines. <i>Therapeutic Drug Monitoring</i> , <b>2013</b> , 35, 608-16	3.2	58
25	Statistical tools for dose individualization of mycophenolic acid and tacrolimus co-administered during the first month after renal transplantation. <i>British Journal of Clinical Pharmacology</i> , <b>2013</b> , 75, 1277-88	3.8	19
24	Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. <i>Thrombosis and Haemostasis</i> , <b>2013</b> , 110, 723-31	7	121
23	Dysregulated proinflammatory and fibrogenic phenotype of fibroblasts in cystic fibrosis. <i>PLoS ONE</i> , <b>2013</b> , 8, e64341	3.7	24
22	Immunomodulatory activity of vardenafil on induced lung inflammation in cystic fibrosis mice. <i>Journal of Cystic Fibrosis</i> , <b>2012</b> , 11, 266-73	4.1	23
21	Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. <i>Transplant International</i> , <b>2012</b> , 25, 41-7	3	73
20	Liquid chromatography-tandem mass spectrometry or automated immunoassays: what are the future trends in therapeutic drug monitoring?. <i>Clinical Chemistry</i> , <b>2012</b> , 58, 821-5	5.5	48
19	A simultaneous d-optimal designed study for population pharmacokinetic analyses of mycophenolic Acid and tacrolimus early after renal transplantation. <i>Journal of Clinical Pharmacology</i> , <b>2012</b> , 52, 1833-43	2.9	32
18	Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitors dose requirements and trough blood levels in stable renal transplant patients. <i>Pharmacogenomics</i> , <b>2011</b> , 12, 1383-96	2.6	119
17	Therapeutic drug monitoring of imatinib. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , <b>2011</b> , 33, 257-8		1
16	Extended release tacrolimus and antiretroviral therapy in a renal transplant recipient: so extended!. <i>Transplant International</i> , <b>2010</b> , 23, 1065-7	3	6
15	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. <i>Pharmacogenomics</i> , <b>2010</b> , 11, 703-14	2.6	80
14	Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>2009</b> , 41, 590-602	5.7	99
13	Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 139-52	3.2	347
12	Multi-site analytical evaluation of the Abbott ARCHITECT tacrolimus assay. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 198-204	3.2	74

11	Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic study. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 734-42	3.2	24
10	Biotransformation enzymes and drug transporters pharmacogenetics in relation to immunosuppressive drugs: impact on pharmacokinetics and clinical outcome. <i>Transplantation</i> , <b>2008</b> , 85, S19-24	1.8	32
9	1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. <i>Pharmacogenetics and Genomics</i> , <b>2007</b> , 17, 873-83	1.9	83
8	The influence of genetic polymorphisms of cytochrome P450 3A5 and ABCB1 on starting dose- and weight-standardized tacrolimus trough concentrations after kidney transplantation in relation to renal function. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2006</b> , 44, 1192-8	5.9	42
7	Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice. <i>Respiratory Research</i> , <b>2006</b> , 7, 134	7.3	77
6	Pharmacology and Use of Immunosuppressants <b>2006</b> , 631-642		
5	Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. <i>Transplantation</i> , <b>2005</b> , 80, 977-84	1.8	89
4	The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. <i>Pharmacogenetics and Genomics</i> , <b>2004</b> , 14, 147-54		368
3	Pharmacokinetic Basis for the Efficient and Safe Use of Low-Dose Mycophenolate Mofetil in Combination with Tacrolimus in Kidney Transplantation. <i>Clinical Chemistry</i> , <b>2001</b> , 47, 1241-1248	5.5	92
2	Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus. <i>Transplantation</i> , <b>1997</b> , 64, 1438-42	1.8	145
1	Microemulsion formulation of cyclosporine in pediatric liver transplantation. <i>Transplantation</i> , <b>1996</b> , 61, 512-4	1.8	10